Cash & equivalents increased 221.8%
Cash & equivalents changed +221.8% from the comparable as-filed period.
$186.3M→$599.6M2 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed +221.8% from the comparable as-filed period.
Revenue changed +21.6% from the comparable as-filed period.
Operating income changed -22.9% from the comparable as-filed period.
Research & development changed +26.5% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.